Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.
作者信息
Heidegger Isabel, Pichler Renate, Heidenreich Axel, Horninger Wolfgang, Pircher Andreas
机构信息
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Cologne, Germany.
出版信息
Transl Androl Urol. 2018 Mar;7(Suppl 1):S132-S134. doi: 10.21037/tau.2017.10.06.
Abstract
摘要
相似文献
1
Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.镭-223用于转移性去势抵抗性前列腺癌：ALSYMPCA试验后的结果及尚存的未决问题
Transl Androl Urol. 2018 Mar;7(Suppl 1):S132-S134. doi: 10.21037/tau.2017.10.06.
2
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
3
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.镭-223 二氯化物在有或无先前多西他赛治疗的去势抵抗性前列腺癌和有症状骨转移患者中的疗效和安全性：来自随机、双盲、III 期 ALSYMPCA 试验的预设亚组分析。
Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17.
4
Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.接受二氯化镭-223治疗的去势抵抗性前列腺癌患者的护理管理
Clin J Oncol Nurs. 2015 Apr;19(2):E31-5. doi: 10.1188/15.CJON.E31-E35.
5
Radium 223 for the treatment of metastatic castration-resistant prostate cancer.镭223用于治疗转移性去势抵抗性前列腺癌。
Arch Esp Urol. 2019 Jun;72(5):500-507.
6
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?镭223：我们如何优化这种用于转移性去势抵抗性前列腺癌的新工具？
Am Soc Clin Oncol Educ Book. 2015:e270-3. doi: 10.14694/EdBook_AM.2015.35.e270.
7
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.镭-223 治疗骨转移去势抵抗性前列腺癌患者的选择：新建议和未来展望。
Clin Genitourin Cancer. 2019 Apr;17(2):79-87. doi: 10.1016/j.clgc.2018.11.008. Epub 2018 Nov 22.
8
Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.转移性去势抵抗性前列腺癌患者接受镭-223 治疗的选择和监测。
Clin Transl Oncol. 2018 Jun;20(6):679-686. doi: 10.1007/s12094-017-1785-0. Epub 2017 Nov 2.
9
Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.镭-223 在转移性去势抵抗性前列腺癌中的最佳应用。
J Formos Med Assoc. 2017 Nov;116(11):825-836. doi: 10.1016/j.jfma.2017.04.005. Epub 2017 Oct 16.
10
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.镭-223 二氯化物治疗有症状去势抵抗性前列腺癌日本患者的 II 期研究。
Int J Clin Oncol. 2018 Feb;23(1):173-180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2.
引用本文的文献
1
Secretion of specific metabolites and changes in miRNA expression in murine osteoblastic cells exposed to α‑radiation.暴露于α辐射的小鼠成骨细胞中特定代谢物的分泌及miRNA表达的变化
Int J Mol Med. 2025 Oct;56(4). doi: 10.3892/ijmm.2025.5602. Epub 2025 Aug 1.
2
Assessing Radiographic Response to Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients.评估转移性去势抵抗性前列腺癌患者的放射性反应的自动骨扫描指数。
J Nucl Med. 2020 May;61(5):671-675. doi: 10.2967/jnumed.119.231100. Epub 2019 Oct 4.
本文引用的文献
1
Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity.镭疗法治疗晚期转移性去势抵抗性前列腺癌：骨骼肿瘤负担的定量评估对临床结局和血液学毒性的预后价值。
J Nucl Med. 2018 Apr;59(4):596-602. doi: 10.2967/jnumed.117.195677. Epub 2017 Sep 1.
2
Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer.预测反应与识别耐药性：改善去势抵抗性前列腺癌患者的治疗结果
Urology. 2017 Nov;109:6-18. doi: 10.1016/j.urology.2017.04.062. Epub 2017 Aug 7.
3
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.来自3期随机化阿法镭（Alpharadin）治疗有症状前列腺癌试验中，二氯化镭-223对去势抵抗性前列腺癌伴症状性骨转移患者的三年安全性。
Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11.
4
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
5
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.镭-223 二氯化物（Ra-223）对住院的影响：来自 3 期随机 ALSYMPCA 试验中放射性配体治疗的疗效研究。
Eur J Cancer. 2017 Jan;71:1-6. doi: 10.1016/j.ejca.2016.10.020. Epub 2016 Dec 6.
6
New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌最佳治疗方案选择的新型生物标志物。
Target Oncol. 2017 Feb;12(1):37-45. doi: 10.1007/s11523-016-0461-6.
7
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.二氯化镭-223的血液学安全性：ALSYMPCA试验中与骨髓抑制相关的基线预后因素
Clin Genitourin Cancer. 2017 Feb;15(1):42-52.e8. doi: 10.1016/j.clgc.2016.07.027. Epub 2016 Aug 8.
8
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
9
Therapeutic radiation and the potential risk of second malignancies.治疗性辐射与潜在的第二恶性肿瘤风险。
Cancer. 2016 Jun 15;122(12):1809-21. doi: 10.1002/cncr.29841. Epub 2016 Mar 7.
10
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
Zotero 插件